G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
May 18 2022 - 10:15AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that Jack Bailey, G1’s Chief Executive
Officer, will provide a virtual corporate presentation during the
H.C. Wainwright & Co. Global Investment Conference. The
presentation will become available at 7:00 AM EDT on May 24, 2022.
This meeting is being held in person and virtually; the webcast of
G1’s presentation will be accessible on the Events &
Presentations page of http://www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology company focused on the development and
commercialization of next generation therapies that improve the
lives of those affected by cancer, including the Company’s first
commercial product, COSELA™ (trilaciclib). G1 has a deep clinical
pipeline and is executing a tumor-agnostic development plan
evaluating COSELA in a variety of solid tumors, including
colorectal, breast, lung, and bladder cancers. G1 Therapeutics is
based in Research Triangle Park, N.C. For additional information,
please visit www.g1therapeutics.com and follow us on
Twitter @G1Therapeutics.
Contacts:Will RobertsVice President, Investor
Relations & Corporate Communications919-907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Sep 2023 to Sep 2024